Sponsor:
Merck Sharp & Dohme LLC
Code:
NCT07554339
Conditions
Non-small Cell Lung Cancer
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Calderasib
Durvalumab
Placebo to MK-1084
Brief summary:
Conditions
Non-small Cell Lung Cancer
Study ID
NCT07554339
Start date
Jun 18, 2026
Status verified date
Nov, 2026
Completion date
Aug 17, 2037
Anticipated
Primary completion date
Dec 15, 2032
Anticipated
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Enrollment
310 participants
Anticipated
Allocation
Randomized
Intervention Model
Parallel Assignment
Primary purpose
Treatment
Arms
experimental: Calderasib + Durvalumab
active comparator: Placebo + Durvalumab
Interventions
Calderasib
Durvalumab
Placebo to MK-1084
Primary outcome measure
Central contacts
Locations
Piedmont Atlanta Hospital ( Site 0121)
Recruiting
Atlanta, Georgia, United States, 30318
Contacts
Study Coordinator
999-999-9999Low Country Cancer Care ( Site 0155)
Recruiting
Savannah, Georgia, United States, 31404
Contacts
Study Coordinator
912-692-2000Duly Healthcare ( Site 0158)
Recruiting
Lisle, Illinois, United States, 60532
Contacts
Study Coordinator
630-545-7760NHO Revive Research Institute LLC ( Site 0118)
Recruiting
Lincoln, Nebraska, United States, 68506
Contacts
Study Coordinator
402-484-4900Rutgers Cancer Institute of New Jersey ( Site 0100)
Recruiting
New Brunswick, New Jersey, United States, 08901
Contacts
Study Coordinator
732-395-8823New York Oncology Hematology P.C ( Site 9000)
Recruiting
Albany, New York, United States, 12206
Contacts
Study Coordinator
518-489-0044WakeMed Raleigh Campus ( Site 0144)
Recruiting
Raleigh, North Carolina, United States, 27610
Contacts
Study Coordinator
919-350-2873Virginia Cancer Specialists ( Site 0114)
Recruiting
Fairfax, Virginia, United States, 22031
Contacts
Study Coordinator
703-208-3110Sponsor
Merck Sharp & Dohme LLC
Last update posted
Nov 12, 2026
Last verified
Nov, 2026
Trial information was received from ClinicalTrials.gov and was last updated on 2026-11-18. This information was provided to ClinicalTrials.gov by Merck Sharp & Dohme LLC on 2026-11-12. Recruitment status is synced daily from ClinicalTrials.gov and may not reflect the sponsor's current status. Confirm during your call.